Can a single antibody turn down the immune storm in ARDS?

NCT ID NCT06513949

First seen Jul 28, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This trial tests whether an antibody called IC14 can reduce dangerous lung inflammation in people with acute respiratory distress syndrome (ARDS), a severe condition where the lungs fill with fluid. Hospitalized patients on a ventilator receive either IC14 or a placebo, and researchers measure oxygen levels and markers of inflammation over 28 days. The goal is to see if blocking a protein called CD14 can calm the immune system and improve breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a monoclonal antibody called atibuclimab (IC14) that blocks CD14 to reduce inflammation
What this could lead to
If effective, IC14 could offer a new way to treat acute respiratory distress syndrome by calming the immune system's overreaction in the lungs.
What could go wrong
This is an early Phase 2 trial with only 56 participants, so results may not apply broadly. Blocking CD14 could also impair the body's ability to fight infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LUNG INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Harborview Medical Center

    RECRUITING

    Seattle, Washington, 98104, United States

  • University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.